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Understanding of the immunobiology of leukemias and lymphomas has been 
considerably aided by two concomitant developments--the generation of a series 
of monoclonal antibodies that define specific surface antigens on tumor cells and 
the identification and characterization of sets of lymphocytes with highly specific 
immunologic functions. 
Immune regulation of chronic B  cell lymphomagenesis has been particularly 
difficult  to  approach  experimentally because  few animal  models  exist.  In  the 
BCL 1 system (1-3), rapidly proliferating id  + (idiotype)  ~ B cells appear to depress 
the  total  number  of both  Ly T  subsets  in  the  spleen  and  LN  as  the  tumor 
progresses (4).  In  the  MOPC  315  myeloma model,  id specific helper and sup- 
pressor T  cells control the differentiation and maturation of MOPC 315 myeloma 
cells, both  by cell contact and  by factors secreted  by both cell subsets  (5-10). 
Both the BCL  1 and MOPC  systems resemble the more rapidly proliferating B 
cell dyscrasias, rather than the chronic B cell lymphomas. 
To  define  the  immunoregulatory  cellular  interactions  that  govern  B  cell 
lymphomagenesis, we have developed an experimental model of chronic B cell 
lymphoma induced by the retrovirus murine sarcoma-murine leukemia-Moloney 
(MSV-MuLV-M). The immunopathology of these B cell lymphomas is similar to 
Waldenstrom's macroglobulinemia in the human since the tumor-bearing C57B1/ 
6  mice  have  elevated  serum  IgM,  a  high  proportion  of mu  +  B  cells  in  the 
mesenteric lymph node and  develop slowly proliferating plasmacytoid-lympho- 
cytic lymphomas two years after injection with retrovirus. Repeated attempts by 
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our laboratory to clone malignant mu ÷ B cells from the primary lymphoma have 
not  resulted  in  the  establishment  of B  cell  clones,  but  rather,  in  a  series  of 
malignant  Thy-l.2  +  Ly-1 ÷  Ly-2,3-  T  cell  clones.  These  T  cell  clones,  when 
incubated with purified B cells in vitro, induced the spontaneous secretion of Ig 
(11), suggesting that the malignant  B  cell might be stimulated  by the T  cell or 
immunoregulatory molecules that it secretes. 
We have now extensively analyzed the immunobiological function of B  lym- 
phoma-associated T  cell clones in vivo and in vitro. In the work to be presented, 
we  demonstrate  that  the  same  subset  of  malignant  Ly-1 +  Qa-1 +  T  cells  is 
repeatedly associated  with  mu  +  B  cell  lymphomas.  This  subset  of T  cells  has 
primitive antigen-independent inducer activity that promotes both hematopoietic 
and lymphocytic differentiation and function. 
Materials and Methods 
Mice.  Female C57B1/6 (B6) mice were obtained from The Jackson Laboratory, Bar 
Harbor, ME. 
Virus.  Murine sarcoma virus B-75, which contains MuLV-Moloney as a helper leuke- 
mia virus (MSV-MuLV-M),  was  kindly supplied by Dr. Jack Gruber, National  Cancer 
Institute, Bethesda, MD, and was stored at -70°C. Each 3 wk-old B6 mouse was injected 
intramuscularly with 0.3 ml of 2  x  10 4 focus-forming units virus per milliliter into the 
right quadriceps muscle. 
T Cell Clones.  T  cell clones were isolated (a) from the mesenteric lymph node (MLN) 
of B6 mice injected two or more years previously with MSV-MuLV-M or (b) from the 
spleens of B6 mice injected 2 wk previously with MSV-MuLV-M. The cells were plated 
at 0.3  cells]well on (2,000  rad irradiated)  B6 splenocytes in  Eagle's  minimal essential 
medium (containing 10% heat-inactivated FCS, 100 U/ml penicillin-streptomycin, 1 mM 
L-glutamine, 5  X  10  -5 M  2-mercaptoethanol, 1% vitamins, and  1% nonessential amino 
acids) in a total volume of 0.1  ml/well. Those cells which proliferated as a result of the 
cloning procedure were analyzed  using the  fluorescence-activated cell sorter (FACS), 
recloned and injected i.p. at log dilutions into normal B6 mice. 
Antisera.  Ly-1, Ly-2, or Thy-l.2 rat monoclonal antibodies were concentrated from 
culture supernatants of hybridoma cell lines 53-7.313 (anti-Ly-1), 53-6.72 (anti-Ly-2), 
and 30 H 12 (anti-Thy-l.2) provided by Dr. N. Warner. Specific binding of these reagents 
to cell surface antigens was determined using rabbit anti-rat F(ab')2 serum conjugated to 
fluorescein isothiocyanate (FITC) (N. L. Cappel Laboratories, CochranviUe, PA). Anti- 
Qa-1  alloantiserum was provided by Dr. L. Flaherty. Binding of the anti-Qa-1 to the cell 
surface was  determined both by using rabbit anti-mouse  F(ab')2  serum  conjugated to 
FITC and protein-A FITC. 
Preparation of Cells for Cell Sorter Analysis.  3-5 ×  10  ~ cells were centrifuged at 300 g, 
the pellets incubated with 0.1  ml monoclonal antibody for 30 min at 4°C, washed 3x in 
cold PBS and centrifuged into a pellet. Following a second 30-rain incubation at 4°C with 
the appropriate fluorescein-conjugated antibody, the cells were washed 3x in cold PBS 
and analyzed using the Becton Dickinson FACS IV (Mountain View, CA). All sera used 
were  ultracentrifuged at  100,000  g  for  20  min  immediately  before  use  to  remove 
aggregates. 
Erythroid Colony-forming Unit Assay (CFU-E).  Bone marrow (BM) and spleen cell suspen- 
sions  were cultured in plasma clots as described by Axeirod et al (12).  5  X  104 bone 
marrow or spleen cells were grown in microtiter wells in the presence of 0.25 U/ml of 
Erythropoietin Step  III  (Connaught  Laboratories, Willowdale,  Ontario),  beef embryo 
extract (Gibco Laboratories, Grand Island, NY),  t.-asparagine (Sigma Chemical Co., St. 
Louis, MO),  1% bovine serum albumin (BSA),  Fraction V (Sigma),  NCTC-109 (Micro- 
biological Associates,  Bethesda, MD),  20% heat-inactivated fetal calf serum (FCS; Irvine 
Scientific Co., Irvine, CA),  modified Eagle's Medium with Hanks' balanced salt solution 908  REGULATION OF  B CELL  LYMPHOMAGENESIS 
(Gibco) and 10% bovine citrated plasma (Gibco). The cultures were incubated for 48 h at 
37°C in  5%  CO~.  The clots were removed from the microtiter wells,  placed on slides, 
fixed with 5% glutaraldehyde, stained with 1% benzidine (Eastman Kodak Co., Rochester, 
NY)  and  counterstained  with  hematoxylin  (Fisher,  Medford,  MA).  The  slides  were 
examined microscopically. Aggregates of eight or more nucleated benzidine-positive cells 
were scored as a colony. 
Granulocyte-Monocyte Colony-forming Unit Assay (CFU-C).  105 BM cells in a total volume 
of 3 ml were cultured in 35 ×  10-mm Falcon petri dishes in McCoy's 5a medium (Gibco) 
containing  0.8%  methyl  cellulose  (Fisher  Scientific  Co.,  Pittsburgh,  PA),  10%  heat- 
inactivated FCS, supplemented with sodium bicarbonate, sodium pyruvate, Eagle's MEM 
vitamins, Eagle's MEM essential amino acids,  nonessential amino acids, L-glutamine, L- 
serine, and L-asparagine. Before plating, 0.2 ml lung conditioned media or endosera were 
pipetted per dish as a source of CSF. Cells were grown for 7 d at 37°C in 7.5% CO~. Cell 
growth was evaluated using an inverted microscope; a  colony consisted of 20 or more 
cells. 
Infection of BM Cultures with MSV-MuLV-M.  Bone marrow cells were obtained from the 
femurs of C57B1/6 mice as previously described (13). The cells were washed extensively, 
and resuspended at a concentration of 10 ×  108 cells/ml. 1 ml of MSV-MuLV-M (2 ×  104 
FFU/ml) was then added per culture, and the cells incubated overnight at 37°C.  24 h 
later, the cells were washed 3×, and incubated in a CFU-E assay (as detailed above). 
Cytolytic Assay.  LSTRA tumor cells (H-2  a) were treated with 150 #Ci sodium chromate- 
51, washed three times with cold PBS containing 5% heat-inactivated FCS, and incubated 
4 h with various numbers Of lymphocytes obtained from either in vitro cultures or directly 
from experimental animals. The percent cytotoxicity was calculated as follows:  experi- 
mental release-spontaneous release/freeze-thaw,spontaneous release. 
In each experiment, normal lymphocytes were incubated with radiolabeled target cells 
to assess normal cell activity. Tumor cells were also incubated in medium to ascertain the 
spontaneous release value. 
Assessment of Plaque-forming Cell Activity.  Spleen cells at 10 ×  106/ml and sheep eryth- 
rocytes at 10% were resuspended in Ca  ++ free buffered salt solution. 50 ~, aliquots of each 
were combined with 50 ), BSS and 50 ~ absorbed guinea pig complement (diluted 1:33 in 
BSS) in Cunningham chambers. Following a 30-rain incubation at 37 °C, the plaques were 
enumerated microscopically. 
Factor Assays.  All cultures were performed in 96-well flat-bottom culture plates (Falcon) 
using RPMI medium supplemented with  10% FCS, L-glutamine (2 mM), penicillin (100 
U/ml), streptomycin (100 U/ml), and 2-mercaptoethanol (5 x  10 -5 M). 
IL-2.  The presence of IL-2 in test supernatants was determined using IL-2-dependent 
T  cell blasts as described (14-16).  In brief, Con A-stimulated T  cell blasts (isolated on 
ficoll-hypaque,  o  =  1.078)  were  cultured  at  2  ×  104/well  for  3  d  with  dilutions  of 
supernatants. Proliferation was measured by incorporation of [SH]thymidine following a 
6-h pulse with 0.5 gCi (specific activity 2 Ci/mM). 
IL-1.  The presence of IL-I was measured using the costimulator assay (17).  5 ×  105 
BALB/c thymocytes were cultured ±  limiting doses (1.25-2.5 ~g/mi) of Con A and test 
supernatants. (Those supernatants that supported proliferation in the presence of Con A 
contained IL- 1  .) 
TRF.  TRF  activity  (18)  was  measured  on  T  cell-depleted  (19)  spleen  cells  from 
C57BI/6  mice,  (modified  from  reference  20).  5  ×  105  T-depleted  spleen  cells  were 
cultured  with  5  ×  105  SRBC  ±  supernatants  for 5  d  and  direct  anti-SRBC/PFC/well 
determined in a plaque assay 
BCGF.  "B cell growth factor (BCGF)" activity was measured using a modification of a 
co-stimulator assay, in which suboptimal doses (5 #g]ml) of LPS were cultured with T- 
depleted  spleen  cells  (3  ×  105/well).  Those  supernatants  that  promoted  cell  growth 
(measured by SHTdR incorporation after 3 d) contained BCGF. RE1NISCH  ET  AL.  909 
Results 
Isolation of Cell Surface Analysis of Retrovirus-stimulated  T  Cell Clones.  In our 
earlier  studies,  we  showed  that  C57B1/6  mice  injected  with  MSV-MuLV-M 
developed Mu  ÷ B cell lymphomas two or more years after injection with virus. 
It was from these mice that the "Clone A" T  cell clones were established (12). 
The following set of experiments was designed to determine whether phenotyp- 
ically similar T  cell clones could be isolated from B6 mice injected with MSV- 
MuLV-M before the development of B cell lymphomas. 
2-3-wk old B6 mice were injected intramuscularly with 5  ×  10 4 FFU MSV- 
MuLV-M.  14 d  later, when the sarcomas induced at the site of inoculation had 
regressed, the mice were killed, the spleens removed, and  splenocytes plated 
directly on irradiated feeder cells. Simultaneously, an aliquot of splenocytes was 
analyzed using the FACS.  One month later, the clones that proliferated were 
analyzed using monoclonal antisera. As seen in Fig.  1, all the clones (designated 
A 
lli~: 
FLUORESCENCE  INTENSITY 
,,=, 
z 
n 
I  | 
'f  I  iI: 
lll,,ll 
FLUORESCENCE  INTENSITY 
il  ' 
FLUORESCENCE  INTENSITY 
FIGURE  1.  T  cell clones were isolated from splenocyte populations of C57BI/6 mice injected 
14 d  previously with MSV-MuLV-M. The clones were first incubated with a  1:50 dilution of 
normal rat serum (  ....  ), anti-Thy-l.2 (~),  anti-Ly-1 (  ), or anti-Ly-2 ( .... ) monoclonal 
antibodies. The cells were then washed, and  incubated with a  1:50  dilution of goat anti-rat 
FITC, washed 3x and analyzed on a  FACS. A and B represent two independently isolated T 
cell clones called  the  MSV-APS series'. C  represents Clone A  incubated  with the identical 
dilutions of normal rat serum ( .... ),  anti-Thy-l.2 (---) anti-Ly-I  (--.-,) or anti-Ly-2 (  ) 
monoclonal antibodies. 910  REGULATION  OF  B  CELL  LYMPHOMAGENESIS 
the MSV-APS series) expressed the Ly-1 and Thy-1.2 lymphocyte differentiation 
antigens. The cells did not express Ly-2,3 nor Ig. This phenotype is identical to 
the clone A  series previously reported (11) demonstrating that the same sub- 
population  of Ly-1 +  T  ceils  was  recovered from  retrovirus-infected animals 
before the onset of lymphomagenesis. The MSV-APS series was then compared 
with clone A to determine the Qa-1 phenotype. As seen in Fig. 2, all the clones 
were Qa-I +, substantiating the hypothesis that T  cell clones isolated from tumor- 
bearing mice or from mice injected with  MSV-MuLV-M were phenotypically 
identical. 
Graded doses of the MSV-APS T  cell clones were injected intraperitoneally or 
intravenously into normal B6  mice. At a dose of 10  x  106 cells, the recipients 
died of immunoblastic T  cell sarcomas -7  d  after injection, proving that  the 
MSV-APS clones, similar to the clone A series, were extremely malignant. 
From these experiments, we concluded that  the injection of C57B1/6  mice 
with MSV-MuLV led to the expansion of an Ly-1 + Qa-1 + subset ofT cells. These 
cells could be cloned in vitro, had the identical phenotype as T  cell clones isolated 
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FIGURE  2.  MSV-APS  i  and 2  and clone A  were  incubated with a  I:10  dilution of normal 
mouse serum (  ) or anti-Qa-1 serum (rim) and subsequently with a  1:50 dilution of rabbit 
anti-mouse F1TC. REINISCH ET  AL.  911 
from  MSV-induced  B  cell  tumors,  and  were  malignant  in  syngeneic  recipient 
mice. 
Modulation of Granulopoiesis  During Lymphomagenesis.  During MSV-MuLV-M- 
induced B cell lymphomagenesis in B6 mice, several immunopathological changes 
occurred.  The mice developed hyperviscosity syndrome, lymphadenopathy, and 
megakaryocytosis.  We  next  analyzed  levels  of  granulopoiesis  in  |ymphoma- 
bearing B6 mice to determine whether a possible interaction might occur between 
the Qa-1 + subset of inducer T  cells and granulocyte precursors. 
1  x  106  bone  marrow  or  spleen  cells  derived  from  normal  B6  mice  or 
lymphoma-bearing B6 mice were cultured for 7 d  in semi-solid media containing 
0.8%  methyl cellulose  in  the  presence  of CSF  to  determine  CFU-C  levels.  As 
seen  in  Table  I,  both  bone  marrow  and  splenic  populations  from  lymphoma- 
bearing B6  mice had  significantly  elevated numbers of CFU-C,  demonstrating 
that granulopoiesis increased during MSV-induced lymphomagenesis. 
Modulation  of Hematopoietic  Function  by  T  Cell  Clones.  We  next  analyzed  the 
effect that the T  cell clones might have on either CFU-C or CFU-E differentia- 
tion.  B6  BM  cells were  mixed with either  in vivo or in vitro passaged clone A 
cells and  the  number of CFU-C ascertained  7  d  later.  As seen in Table II, the 
addition of either in vivo or in vitro passaged clone A cells resulted in significantly 
TABLE  I 
Analysis of CFU-C Activity in the Bone Marrow and Spleen During 
MSV-MuL V-M-induced Lymphomagenesis 
Normal  Normal BM  MSV BM  spleen  MSV spleen 
45 +6.9  94.7-+10.1  0  6.04-2.5 
524-10.5  98.34-6.3  0  5.34-0.7 
Numbers of CFU-C 4- SEM per 105 bone marrow or spleen cells plated 
are shown. Cells isolated from B6 mice with MSV-MuLV-M induced  B 
cell lymphomas or  from age- and  sex-matched  normal  B6  mice were 
individually assessed for precursor cell activity. 
TABLE  II 
Effect of Clone A on Granulopoiesis 
BM 
Percent added clone A cells 
+10  +100  +300 
46.7+7.2*  50.3+7.3  1064-3.4  844-5.7 
(107)  (225)  (178) 
52.54-8.5*  73.54-8.6  90.54-10.3  1234-15.3 
(140)  (172)  (232) 
CFU-C +  SEM (percent  control  in parenthesis) per 105 bone marrow  cells 
plated. 
* Normal bone marrow cells were mixed with in vitro passaged clone A cells. 
Clone A cells were irradiated  with  10,000 rad before cocutture  with bone 
marrow cells. 
* Normal bone marrow cells were cocultured  with clone A cells that had been 
maintained  in vivo. Clone A cells were irradiated  with  10,000 rad before 
coculture with bone marrow cells. 912  REGULATION  OF  B  CELL  LYMPHOMAGENESIS 
elevated numbers of CFU-C. Further experiments showed that the clone could 
not substitute for colony-stimulating factor (CSF), nor did it release factors that 
promoted CFU-C differentiation. 
To determine whether the inducer T  cell clones would influence erythropoi- 
esis, the following experiments were performed. 5 ×  10  4 BM cells were obtained 
from normal B6 mice and were incubated with 2.5 X  103, 5 X  103, 2.5 X  104, or 
8 x  104 (10,000 rad) irradiated  clone A cells. As seen in Fig. 3, the addition of 
clone A cells to syngeneic BM cells resulted in enhanced erythropoietin-depend- 
ent erythropoiesis. Further experiments showed that the clone could not substi- 
tute for erythropoietin  nor did it release factors that promoted CFU-E differ- 
entiation.  In addition, infection of B6 BM cells with virus did not enhance CFU- 
E differentiation, leading us to conclude that the clone per se, and not factors or 
virus, promoted erythroid differentiation. 
These two sets of experiments showed that clone A stimulated the differentia- 
tion of both erythroid and  granulocytic precursors in the  bone marrow.  More 
importantly,  these data showed that  this immunobiological function of clone A 
closely paralleled the in vivo situation since tumor-bearing mice had dramatically 
elevated levels of CFU-C precursors.  Coupled with earlier results showing that 
the T  cell clones enhanced spontaneous Ig secretion by B cells (11), it appeared 
that we had isolated a series of antigen-independent  inducer T  cell clones. 
Enhancement  of Antigen-stimulated  Systems  by  Inducer  T  Cell  Clones.  To  test 
whether clone A could enhance the immune response to antigen, B6 mice were 
immunized intraperitoneally  with SRBC plus/minus clone A.  3, 5, or 7 d  later, 
the mice were killed and the splenocytes analyzed for mu and gamma secreting 
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FICURE 3.  The effect of  clone A on erythropoiesis. 5 x  104 C57B1/6  bone marrow cells were 
incubated with increasing numbers of (I 0,000 tad irradiated) clone A cells in a CFU-E assay. 
48 h later, the clots were removed, fixed, stained with 1% benzidine, and counter-stained  with 
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PFC response to SRBC in vivo.  As seen in Figs.  4  and  5, clone A  significantly 
enhanced the gamma PFC response to SRBC in vivo. 
To determine whether inducer function could be detected during the gener- 
ation of alloreactive cytotoxic cells, B6 mice were injected intraperitoneaUy with 
a suboptimal dose of LSTRA tumor cells (1  x  10 8) and varying doses of lethally 
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FlOUlt~  4.  Enhancement  of  IgM  response  by  clone  A.  Splenocytes  from  C57B1/6  mice 
S  immunized with SRBC (O) or SRBC plus 5  ×  10  (10,000  rad irradiated) clone A  (r-I) were 
harvested 1, 3, 5, or 7 d following immunization and assayed for PFC using theJerne plaque 
technique. Results represent the number of PFC/15 x  10~splenocytes plated. 
800  uJ 
>- 
L) 
o  700 
Z 
I.U 
._1 
o_  600  ¢n 
~o  500 
x 
to 
--  400 
i  300 
O 
_J  a.  200 
I-.- 
(.) 
~  100 
Z  I  I  "I-  I  I  I  I 
I  2  3  4  5  6  7 
DAYS  POST  IMMUNIZATION 
FmERE  5.  Enhancement  of  lgG  response  by  clone  A.  Splenocytes  from  C57B1/6  mice 
immunized with SRBC (O) or  5  SRBC plus 5  ×  10  (10,000 rad irradiated) clone A  (F]) were 
harvested 1, 3, 5, or 7 d later and assayed for indirect PFC using theJerne plaque technique. 
Results represent the number of PFC/1.5 x  106 splenocytes plated. 914  REGULATION  OF  B  CELL  LYMPHOMAGENESIS 
irradiated  clone  A  cells  i.p.  As  seen  in  Fig.  6,  alloreactivity  was  significantly 
enhanced when the mice were injected with clone A cells plus LSTRA. Moreover, 
the enhancing effect was dose dependent. Repeated experiments confirmed that 
as few as  104 clone A  inducer cells enhanced alloreactive CTL function in vivo. 
However, the injection of clone A did not enhance syngeneic CTL activity even 
when  B6 mice were challenged  with  TNBS-modified EL4 cells +  (10,000  rad 
irradiated) clone A. 
Immunoregulatory  Factors Released  by Clone A.  To determine whether  factors 
were  released  from  clone  A  cells  that  might  mimic  the  activity of the  clone, 
supernatants  were obtained  from  clone  A  cultures  grown  for  48  h  in  RPMI 
1640, 10% heat-inactivated FCS, penicillin-streptomycin, and 1 mM L-glutamine. 
Various doses of supernatant  were added at the initiation  of an in vitro sensiti- 
zation and  the generation  of alloreactive  CTL assessed at  the  end of a  5-d in 
vitro sensitization.  As seen in  Fig.  7,  the addition  of as little as 0.25  ml (10%) 
supernatant  at the initiation  of an in vitro sensitization  resulted in significantly 
elevated CTL function. 
It should be emphasized that clone A was isolated from an animal bearing an 
MSV-induced B cell lymphoma and that  B6 mice injected with MSV-MuLV-M 
as weanling  mice  develop  indolent  B  cell  lymphomas  only two or more years 
following  virus  injection.  We  suspected  that  the  repeated  association  of the 
malignant  Lyl + T  cells with the mu + B cell meant that the T  cells could support 
B cell proliferation.  To test this hypothesis directly, supernatants  derived from 
clone  A  were  extensively analyzed  for  IL-1,  IL-2,  TRF,  or  BCGF  activities. 
Repeated experiments showed that the clone did not secrete IL-1, IL-2 or TRF. 
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FIGURE  6.  Enhancement of alloreactive CTL  function  in  vivo by clone A.  C57B1/6  mice 
were immunized with  1  x  108  LSTRA tumor cells 4-  (10,000  rad  irradiated) clone A  cells• 
The mice were killed 10 d  later, and their splenocytes assessed for CTL reactivity and Cr  5L 
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FIGURE 7.  Enhancement of alloreactive CTL function by the addition of clone A  superna- 
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splenocytes at a  2:3 ratio. Graded doses of clone A  supernatant were added at the initiation 
of the in vitro sensitization. 5 d later, the flasks were harvested, and the CTL activity in each 
group assessed on CrSLlabeled LSTRA ceils. 
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FIGURE 8.  3  X  10 ~ anti-Thy-l.2,  anti-Ly+-l.2  +  C'  treated  C57B1/6  splenocytes  were 
incubated +  5 #g/ml LPS/welI. 0-50% vol/vol (v/v) clone A supernatants were added, and SH 
TdR uptake measured 3 d later. 
However, as seen in Fig. 8 and Table II, clone A  did secrete a factor promoting 
LPS-dependent B cell proliferation. 
Discussion 
These  results demonstrate  that a series of malignant  Ly-1 ÷ Qa-1 ÷ inducer T 
cell clones can repeatedly  be isolated from B6 mice injected with MSV-MuLV- 
M.  The prototype clone,  clone A,  isolated from a  B6  mouse bearing an  MSV- 
MuLV-M-induced  B  cell  lymphoma,  expresses  the  identical  phenotype  and  is 
also malignant in vivo. Extensive functional analyses of this clone show that: (a) 
erythropoiesis  and  granulopoiesis  are  enhanced;  (b)  humoral  and  cellular  re- 
sponses  in  vivo are  amplified;  and  (c)  factors  are  secreted  that  enhance  LPS- 
dependent B cell proliferation and CTL function. Conversely, factors prepared 
identically from the clones have no effect on erythroid or granulocytic matura- 916  REGULATION OF  B CELL LYMPHOMAGENESIS 
tion,  or B cell secretion of immunoglobulin.  The  factors do not contain  IL-1, 
IL-2, or TRF. 
Several  phenomena  remain  unresolved  in  this  model.  Although  there  is  a 
continual association of Thy-l.2 + Ly-1 + inducer T  cells with malignant  B cells, 
the  T  cell  compartment  appears  to be a  minor  component  of the  tumor  cell 
population  when  the cells are  "immunophenotyped."  In vitro,  only the T  cells 
proliferate  probably because the  B cells are  deprived of BCGF.  The  fact that 
clone A cells are extremely malignant when injected following cloning raises the 
important question of what regulates their proliferation during lymphomagene- 
sis.  Extensive  experiments  in  our  laboratory  have  shown  that  incubation  of 
tumor-derived  B cells with  clone A  or unselected Ly-1 + T  cells obtained from 
MSV-MuLV-M-infected B6 mice did not suppress the proliferation of T  cells in 
vivo or in vitro.  We are now testing the hypothesis that  Fc receptors on the T 
cell clones may be mu specific or that  Ly-1 + Qa-1 + T  cell proliferation  in this 
tumor model may be directly suppressed by antigen-stimulated  B cells (21). 
A  separate  question  is  whether  or  not  mu  + B  cell  lymphomas  require  the 
functional interaction of the Ly-1 + Qa-1 ÷ T cell subset for their sustained growth. 
The BCGF data support the view that the clones make a factor that stimulates B 
cells, although whether B cell growth is restricted solely to the mu  + subset is not 
entirely clear.  In fact, the possibility exists that this subset of Ly-1 ÷ T  cells (of 
which clone A  is a prototype) may be idiotypically restricted in its help and can 
function  only via an  id ÷ B  cell.  What  factor(s) promotes the differentiation  of 
CTL in vitro is also puzzling since we know that the cells do not make interleukins. 
The point should additionally be made that supernatants collected from clone 
A  cultures  contain  MuLV-M.  Evaluation  of the clone's high  molecular weight 
DNA as a transfectant revealed that it lacked significant transforming activity in 
contrast  to other  B or T  cell tumors.  In  fact,  when  digested with a  variety of 
restriction  endonucleases,  the transforming activity of clone A  DNA remained 
extraordinarily low (22), perhaps reflecting the fact that weakly oncogenic viruses 
such as MSV-MuLV-M require long latent periods or multiple oncogenic events 
for oncogenesis to occur. 
Relative to the last point, our results raise the fundamental  question of what 
constitutes a  malignant  cell.  In  a  separate animal  system, we have shown that 
BALB/cBy mice infected with MSV-MuLV-M develop massive splenic immuno- 
blastic  (Ly-1 ÷)  T  cell  sarcomas  (23).  Upon  repeated  cloning,  however,  only 
immature  malignant  monocytes  can  be  recovered,  all  of which  anomalously 
express the class I antigen Qa-2 (24, 25). Since these monocytes present protein 
antigen  that  promotes  Ly-1 +  T  cell  proliferation  (26),  we  believe  that  the 
monocyte, and not the T  cell, is malignant.  In this newly discovered model we 
have just presented,  the  Thy-l.2 ÷ Ly-1 + Qa-1 + T  cell  subset  may be initially 
transformed by retrovirus. This subset, in turn, promotes the proliferation of B 
cells via the  constitutive production  of BCGF and  other,  as yet unrecognized, 
signals.  Thus,  excessive B  cell  proliferation  may be due  to a  minor  subset of 
malignant  T  cells that  continually stimulate their  normal  growth.  Studies with 
B6 nude mice should resolve whether or not the B cell in this retrovirus model, 
requires the function of mature Ly-1 ÷ Qa-1 + T  cells for its sustained growth. 
The fact that  Qa-1 + but not Qa-1- T  cells are repeatedly cloned from the B REINISCH ET AL.  917 
lymphoma cell population  (or from MSV-infected mice) is striking. In detailed 
FACS analyses the pattern of T  cell compartment expansion during lymphoma- 
genesis is invariant. The Thy-l.2  + Ly-1 + Qa-+l  subset expands while, simulta- 
neously, the  Ly-23  ÷ subset  becomes  virtually  undetectable.  This  observation 
suggests that the differentiation of Ly-23  ÷ T  cells is actively suppressed during 
lymphomagenesis and/or that the Lyl  Qa-1 + subset proliferates in response to 
viral antigen "chronically" presented by the macrophage and/or B cell. Earlier 
data showing that clone A promotes the secretion of Ig by highly purified normal 
B cells (11) substantiates reports that this Qa-1 + subset of Ly-1 + cells is involved 
in delivering helper signals to B cells resulting in secretory differentiation (27, 
28).  How  the complex interaction between the Thy-l.2  + Ly-1 + Qa-1 + T  cell 
subset and Qa-1- subset (29) shifts during lymphomagenesis can only be resolved 
when the individual Qa-1 + and Qa-1- subsets are positively selected from Ly-1 +- 
enriched T cell populations, and evaluated in vitro using defined antigen systems. 
Moreover, it is now evident that the expansion of Ly-1 + Qa-1 + or Qa-1- subsets 
depends upon underlying cellular pathology.  In MRL/Ipr mice, for example, 
the Ly-1 + Qa-1-  subset proliferates during autoimmune lymphomagenesis  ~ in 
contrast to the model just presented. 
Another emerging fact is that the lineage of B cells in B cell tumors is clonal 
(31-33),  while the associated T  cell sets remain quite heterogeneous (34-36). 
Although we expected to recover a mu  ÷ B cell from a Waldenstr6m's-like lesion, 
we did not expect to clone a restricted subset of malignant Ly-1 + Qa-1 + T  cells. 
The repetitive B-Ly-1 + Qa-1 + T  cell association may explain why patients with 
Waldenstr6m's  macroglobulinemia  may develop  immunoblastic cell  sarcomas 
following aggressive therapy (37,  38).  In fact, we would predict, in  this latter 
circumstance, that T  cell IBL sarcomas would express the T3  T4 phenotype. 
Data  in  the  human  system further show  that  patients  with  cutaneous T  cell 
lymphomas may simultaneously develop a plasmacytoma (39) and that patients 
with "smoldering" adult T  cell leukemias, which are OKT-1 +, OKT-3 +, OKT-4  +, 
and OKT-710 + have hypergammaglobulinemia (40). This observation suggests 
that excess helper function, in  the presence of a  second signal,  may "drive" a 
subset of B cells toward malignancy. 
One final point should be emphasized. The pathologic classification of non- 
Hodgkins lymphomas has been and clearly remains controversial (40,  41).  No 
matter which classification scheme used, the fact remains that malignant lympho- 
mas are comprised of immunologically active subpopulations of cells that interact 
during lymphomagenesis. Our work and that of others supports the view that 
extensive functional characterization of subsets of cells residing within the tumor 
is essential in understanding the immunobiology of the NHL. 
Taken  together,  our  data  show  that  this  animal  model  of plasmacytoid- 
lymphocytic lymphoma consists of two cells: mu-bearing B cells and a subset of 
malignant inducer T  cells that express Qa-1.  The fact that the clone secretes 
BCGF suggests that the interaction between the two cell subsets may be obligatory 
in maintaining B lymphoma cells. 
2  Cronin, P., A. Sing, V. Kelley,  L. Glimcher,  and C. L. Reinisch. 1984. Expansion  of  an Lyl+Qal  - 
subset of T cells during autoimmune  disease: the result of inappropriate Ia expression. Submitted 
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Summary 
A  series of Thy-l.2  ÷ Ly-1 ÷ Qa-1 + malignant T  cell clones have been isolated 
from murine sarcoma virus-murine leukemia-Moloney (MSV-MuLV-M)-induced 
B cell lymphomas or from MSV-MuLV-M-infected B6 mice. These T  cell clones 
enhance both antigen-independent and -dependent  lymphocyte differentiation 
and function. They also induce the differentiation of granulocytes and erythro- 
cytes in  the  stem  cell  compartment,  a  function  that  parallels  the  immunopa- 
thology  of the  disease  in  vivo.  The  malignant  T  cell  appears  to  sustain  B 
lymphoma growth  in  vivo by releasing a  factor (BCGF)  that  promotes  B  cell 
proliferation. 
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